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ABSTRACT  
Cancer is one of the leading causes of death which accounts for 13% of total deaths, worldwide.  Colorectal and Breast cancer fall under main 
categories according to World Health Organisation (WHO) cancer facts sheet 1. The need to understand the expression of clinical biomarkers in 
breast cancer and colon cancer is necessary for diagnosis and therapeutic response. In this article, the expressions of histone H1 and TP53 
biomarkers were established for four different colon cancer cell lines and compared with the expressions of MCF7 cell line. The results show 
varied expression of Histone H1 along with TP53 markers among the cell lines. The results suggest that the linker Histone H1 has shown 
nuclear localization in HCT 116p53 wt (wild type) cancer cell line whereas it has shown cytoplasmic distribution in the respective nu ll type cell 
line with intense expression. The result also suggests that a localized distribution in HRA19 cells and a diffused distribution in SNU-C2B cell 
line. These established results were compared with the expression of the biomarkers in MCF7 in order to get a better understanding. 
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1.1 Biomarkers: A biomarker is a measurable substance 
which helps in depicting a normal or abnormal biological 
system by analysing chemical modification in biomolecules. 
A cancer biomolecule is a tool to measure the risk of 
developing cancer in any specific tissue. It helps in guiding 
clinical decision making while measuring the risk of 
progression or potency of therapy of a cancer. Generally 
biomarkers are classified into Predictive, Prognostic & 
Diagnostic biomarkers2.  
1.2 Tumour Protein TP53 and Cancer 
TP53 is an essential protein which functions as ‘tumour 
suppressor’ in multicellular organisms. It is denoted as p53 
or TP53 gene and is located on the short arm of chromosome 
17 encodes TP53 protein whose chief function is to prevent 
genomic mutations while conserving the stability of the 
genome 3. Most of the mutations hinder the ability of TP53 to 
bind to the target DNA, further on blocking the 
transcriptional activation, indicating a ‘recessive loss of 
function mutation’. Apart from genomic conservation 
function, TP53 plays other roles as anticancer functions, 
apoptosis etc. Likewise people who inherit only one 
functional copy of the gene are at risk of developing early 
tumours 4. The TP53 tumor suppressor protein plays a vital 
role in cellular proliferation.  
 
1.3 H1 Linker Histones 
Linker histones are located in the outer surface of the 
nucleosomal structure in a chromatin fibre and are known to 
be involved in compaction of the fibre and in regulating 
chromatin higher order structure 5. These histones are not 
conserved across species and undergo post translational 
modifications on their tail regions. The variant forms of 
linker histones and their modifications have been shown to 
regulate developmental and differentiation programs6. 
Research has been going on to discover the relation between 
the linker histone H1 and cancer, establishing the findings 
and simultaneously generating further questions to be 
addressed. Many important findings have been established 
based on the research work in this area emphasizing the 
relation between cancer, linker histone H1 and tumour 
suppressor p53 gene.  
1.4 MCF7 Breast Cancer Cell Line: 
Breast cancer accounts for 23% of the total cancer cases and 
is a frequent malignancy which results to 14% of the cancer 
deaths. Michigan Cancer Foundation-7 (MCF 7) cells are used 
for this comparative study. They are widely used in Estrogen 
Receptor (ER)-positive tumor research experiments 7. 
1.5 Colon Cancer Cell Lines:  
HCT 116 wt, HCT 116 p53 null, HRA19 & SNU-C2B cell lines 
are chosen for this study. The study also involves Small 
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interfering RNAs (siRNAs) and scrambled siRNA along with 
the expression of TP53 and H1 Histones among these cell 
lines. siRNA is able to regulate the expression of genes 
through a phenomenon as RNA interference (RNAi) or 
silencing RNA 8. Small interfering Ribonucleic Acid 
(siRNA), is a class of double-stranded RNA molecule, and 
generally consist 21 nucleotides, which can be used to 
"interfere" with the translation of proteins by binding to and 
promoting the degradation of messenger RNA (mRNA) at 
specific sequences 9. While studying transfection activity of 
SiRNA, scrambled scRNA is used. 
Experimentally, an attempt is being made to investigate the 
connection between the TP53 tumour suppressor protein 
and linker histone H1 expression in colorectal cancer cell 
lines to find the probable links in the cancer mechanism and 
diagnostics. 
The aim of the work is to analyse the significance of linker 
histone H1 in colon cancer progression and the signalling of 
H1 through tumour suppressor gene TP53 and to compare 
with that of MCF7 cell lines.  This work is focussed on 
investigating the influence of linker histone modifications in 
colon cancer and to compare the expression of p53 & H1 on 
MCF7 & HCT116 wild & null type, HRA19 & SNU-C2B colon 
cancer cell lines with Cell and tissue level experiments to 
understand the expression patterns of linker histones during 
the malignant and metastatic states of colon cancer. Cell 
culture, confocal microscopy and histopathology have been 
used to investigate the same. Here the focus of the research 
is to compare the expression among two types of cancer cell 
lines; MCF-7 and colorectal cell lines- HCT116 p53 wt, 
HCT116 p53-/-, HRA19 and SNU-C2B and colorectal cancer 
tissues. Cell lines of malignant colon cancer show varied 
levels of linker histone expression in the absence of the 
tumour suppressor p53 and at metastatic stages. Cancer 
tissues show differential expression of H1 and are being 
investigated in detail. 
The experiment goes on first with the culturing of the above 
mentioned four cell lines and noting the expression and 
variations of the linker histone H1 expression in the 
respective cell lines by Immunofluorescence staining and 
confocal microscopy imaging. The difference in level of 
intensity of H1 expressions in the following four cell lines 
indicates towards the role of the effect of the different TP53 
mutations in each of the respective four colorectal cancer cell 
lines as found for these variations. Based on this, silencing 
the TP53 tumour suppressor gene is attempted in the above 
mentioned cell lines by siRNA (small interfering or short 
interfering or silencing RNA) transfection followed by 
looking at the expression levels of H1. This will help validate 
the role of TP53 in H1 expression in the colon cancer cell 
lines. 
2. MATERIALS AND METHODS 
In order to investigate the linker histone H1 profile in colon 
cancer, the malignant colon cancer cell lines were used. Cell 
culture, Immunofluorescence and Confocal microscopy were 
used for the experimental analysis followed by image 
processing with help of Dextrose Technologies. 
2.1 Cell culture 
Malignant human colon cancer cell lines HCT116 wt (having 
wt p53), HCT116 p53-/- and p53 mutant cell lines HRA19 
(Agr273His) and SNU-C2B (Arg273His) from ATCC. 
HCT116wt cell line was cultured in RPMI-1640 
supplemented with 10%FBS and the remaining cell lines 
were cultured using DMEM (Dulbecco's Modified Eagle 
Medium) supplemented with 10%FBS 10.  
30,000 cells from each of the cell lines were plated in 35mm 
cover slip stuck petridishes and allowed to grow for 24hrs 
and then taken for Immunofluorescence. 
Table I. Colon cancer cell lines with their TP53 genes 
status 
Cell Line Status of p53 gene 
HCT 116 wt p53 wt 
HCT 116 p53  null p53 -/- 
HRA19 p53 with Arg273His mutation 
SNU-C2B p53 with Arg273His mutation 
 
2.2 Immunofluorescence  
After the growth period of 24hrs, immunofluresence 
protocol was followed for further processing. The medium 
was aspirated and after washing with 1x PBS (2-3 times), 
cells were fixed with 4% paraformaldehyde (10 mins). After 
PBS wash cells were permeabilised with 0.1% Triton X-100 
in 1x PBS. Blocking is done with 5% BSA in PBS for 1 hour at 
RT. Primay antibody against H1 (Anti-H1 (AE-4) mAb, Santa 
cruz Biotechnology Inc.) was added and kept in 4°C for 
overnight. After PBS wash the next day, secondary antibody 
(Anti-Mouse IgG – AlexaFluor 647) was added and incubated 
for 1 hour RT. DAPI staining was performed and incubated 
for 10 minutes and then the cells were taken for imaging 11. 
2.3 p53 siRNA Transfection 
2x 105 cells were plated /ml and kept for overnight 
incubation. After 24hrs, 50nm each of p53siRNA and p53 
scrambled siRNA were transfected into the cells with 
DharmaFECT transfection media. Initially, 50nm of siRNA is 
added to 2 µL of Dharmafect is added to 100 µL of optiMEM 
and the vials are kept for 5 mins at room temperature. 
Meanwhile the medium is aspirated from the plates and later 
900 µL of optiMEM is added to the plates. Then the siRNA-
Dharmafect transfection mixture is added to the cells and 
incubated for 48hrs. After 48hrs, cells were trypsinised and 
replated at a concentration of 3x104 cells /ml and incubated 
overnight (4% CO2 ; 37 °C). The cells were then taken 
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3. RESULTS  
3.1 Phase I. Linker histone H1 expression in malignant colon cancer cell lines (human) 
 
Figure I. Nuclear localization of Histone H1 in malignant HCT 116 P53 wild type colon cancer cell line 
 
 
Figure II. Cytoplasmic distribution of Histone H1 in malignant HCT 116 p53 null type colon cancer cell line 
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Figure III. Localized distribution of Histone H1 in malignant HRA19 colon cancer cell line 
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3.2 Phase II. Linker histone expressions in view of transfection with siRNA and scrambled (sc)RNA in human colorectal 
cancer cell lines 
 
Figure V. Expression of Histone H1 in HCT116 p53 in siRNA cell nuclei. 
 
 
Figure VI. Expression of Histone H1 in HCT116 p53 in scRNA cell nuclei. 
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Figure VII. Expression of Histone H1 in HRA19 p53 in siRNA cell nuclei. 
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4. DISCUSSIONS: 
1. From figure I, it is evident that Linker histone H1 shows 
nuclear localization (qued at nucleoli)  in HCT 116 p53 
wt colon cancer cell lines whereas HCT116 p53 -/- 
showed more of cytoplasmic distribution (figure II), 
suggesting the role of H1 for localization. It is also 
obvious that the intensity of the expression is high in 
null type when compared with the wild type. Figure III 
depicts that HRA19 cancer cell lines exhibits a localized 
distribution while SNU-C2B reveals a diffused 
distribution of the linker histone Hi (figure IV). 
Intensity of histone H1 distribution in SNU-C2B cells is 
high. 
2. Expression of H1 in HCT1116 wt p53 siRNA/scRNA had 
not showed much difference from the phase I 
experiments (figure I- IV) on HCT116wtp53 and 
HCT116p53-/- as observed in the images. HRA19 
siRNA cell line has shown diffused expression of 
histone H1 to the cytoplasm, it is not in the case of 
HRA19 cell lines in the previous experiments with 
localized distribution. HRA19 scRNA has shown 
expression of H1 in cytoplasm but not as much as 
evident as the siRNA transfected cell lines. The 
intensity of expression is more in the HCT116p53wt 
transfected cell lines than the HRA19 cell lines. 
Cell and tissue level experiments have been done to 
understand the expression patterns of linker histones during 
the malignant and metastatic states of colon cancer. Cell 
culture, confocal microscopy and histopathology have been 
used to investigate the same. 
Corresponding to the above experimentation, a comparative 
analysis is done with MCF7 cancer cell line: various research 
articles are summarised as follows; 
3. According to Sean W. Harshman. et.al, the neoplastic 
MCF-7 cell line has a greater number of histone H1.4 
phosphorylations. They treated MCF7 cells with 70 nM 
estradiol and conducted LC-MS to identify the changes 
in histone H1 phosphorylation. The data showed an 
increase in number of histone H1 phosphorylations 
detected in response to estradiol when compared to the 
untreated MCF-7 cells 13. 
4. Andrea Izquierdo-Bouldstridge et.al, suggests that 
expression of genes are altered as a result of Knocking 
down (KD) of each H1 variant in breast cancer cells. It 
also showed H1.2 and H1.4 KDs being most deleterious 
while exhibiting precise proliferations 14. 
5. Vani G et.al, investigated the effects of exogenous 
histone H1 on estrogen receptor (ER) status of human 
breast cancer MCF 7 cells in presence and absence of 
estrogen. The current study revealed that treatment 
of exogenous histone H1 brings a significant decrease 
in the estrogen receptor which plays a vital role in 
chemotherapeutic treatment of breast cancer 15.  
6. Characterizing of H1.2 in MCF7 Cell is summarized as 
cycle arrest in G1 Phase while reduction in nucleosome 
spacing according to a research article penned by Xin 
Ye. Et.al 16. 
7. A familiar tumor suppressor gene TP53 is involved in 
breast cancer with various mutated genes. 
Expression of TP53 is more frequent with higher 
proliferation rate in Estrogen receptors-negative 
(ER¯). Dysfunction of TP53 is a vital incidence in 
breast cancer 17. 
8. Noa Rivlin et. al., put forward that most TP53 
alterations is due to point mutations which yields a 
mal-functional proteins gets accumulated in breast 
tumor cells. The incidence of TP53 mutations ranges 
from 15 -71% in breast tumours. Their work postulates 
that TP53 mutations at T1 stage tumours are 
uncommon while the frequency in T3 stage is high 4. 
9. According to Torres CM, et al proposes that the histone 
levels of H1 varied significantly among various tumor 
cells. Glioblastoma and breast cancer cells were found 
out to be more hostile tumors with the highest 
proportion of cells while having low levels of H1.0 18. 
10. Elledge R.M, et.al., suggests that the alteration in TP53 
suppressor genes is high and hence it plays a vital role 
in the development of breast cancer while accelerating 
more rapid cell proliferation on loss of TP53 
suppressing activity 19.   
11. According to the report postulated by Massimo 
Negrini,et.al., it is evident that a minimum of two 
genetic events are necessary to convert tumor 
suppressor genes on chromosome 17 which aids in the 
development of  breast cancer 20. 
12. Research work of Melissa A Troester infers that the 
expression of 747 genes correlates directly with p53 
status in Breast cancer cell lines 21. 
5. CONCLUSIONS 
Cell lines of malignant colon cancer show varied levels of 
linker histone expression in the absence of the tumour 
suppressor TP53 (p53) and at metastatic stages. Cancer 
tissues show differential expression of H1 and are being 
investigated in detail. The results of these cell lines showing 
differential molecular responses provide a great impact on 
the diagnosis, prognostication, and tumor-targeted cancer 
therapy. Comparison of biomarkers of H1, TP53 & siRNA 
signalling in MCF7 Breast cancer and HCT116, HRA & SNU-
C2B colon cancer cell lines denotes tumor grades. 
Interactions and expressions of H1 play significant role in 
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